Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance

American Heart Journal

Volumn 132, Issue 4, 1996, Pages 783-789

  Jeng, Jing Ren ^a   Sheu, Wayne Huey Herng ^a   Jeng, Chii Yuan ^a   Huang, Shyuh Hyei ^a   Shieh, Shyh Ming ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; DOXAZOSIN; INSULIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFICACY; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029861133     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90312-9     Document Type: Article

References (30)

1. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pederinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.
2. Fuh MMT, Shieh SM, Wu DA, Chen YDI, Heaven GM. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med 1987;147:1035-8.
3. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor 1 (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-8.
4. Gleerup G, Winther K. Decreased fibrinolytic activity and increased platelet function in hypertension: possible influence of calcium antagonist. Am J Hypertens 1991;41:168S-71S.
5. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986;2:250-3.
6. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabetes Metab 1987;13:331-6.
7. Cubeddu LX, Pool JL, Bloomfield R, Klotman PE, Pickering BI, Wombolt DG, Nelson EB, Halperin A. Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. Am J Hypertens 1988;1:158-67.
8. Shieh SM, Sheu WHH, Shen DC, Fuh MMT, Chen YDI, Reaven GM. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992;5:827-31.
9. Westheim A, Daae LNW, Kierulf P, Brusletto B, Holme I, Syvertsen JO. Selective α-1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects. J Hypertens 1990; 8(suppl 5):S41-S46.
10. Jansson JH, Johansson B, Boman K, Nilsson TK. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol 1991;40:321-6.
11. Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast acting inhibitor (PAI-1). Thromb Haemost 1989;59:329-32.
12. Rånby M, Sundell IB, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989;62:917-22.
13. Eriksson E, Tengborn L, Risberg B. The effect of various anticoagulant/ antiplatelet mixtures on determination of plasminogen activator inhibitor, platelet proteins and hemostasis parameters. Thromb Haemost 1989;61:511-6.
14. Rånby, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986;32:2160-5.
15. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen E. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988;71:220-5.
16. Wilman B, Mellbring G, Rånby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983;127:279-88.
17. Chimielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor for tissue plasminogen activator in plasma. Thromb Res 1983;31:427-36.
18. Sheu WHH, Shieh SM, Shen DC, Fuh MMT, Jeng CY, Chen YDI, Reaven GM. Effect of pravastatin treatment on glucose, insulin and lipoprotein metabolism in patients with hypercholesterolemia. Am Heart J 1994;127:331-6.
19. Shen SW, Reaven GM, Farquhar J. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970;49:2151-60.
20. Kooistra T, Bosma P, Tons H, van den Berg A, Meyer P, Princen H. Plasminogen activator inhibitor 1: biosynthesis and mRNA levels are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989;62:723-8.
21. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990;10:1067-73.
22. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decrease the high plasminogen activator inhibition capacity plasma insulin and triglyceride levels in non diabetic obese subjects. Thromb Haemostas 1987;57:326-8.
23. Sundell IB, Dahlgren S, Rånby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989;3:51-3.
24. Spelzer W, Langer W, Pschaick A, Selmayr E, Ibe B, Nowacki PR, Muller-Bergaus G. Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program Throm Res 1988;57:543-55.
25. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-9.
26. Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: different effects of calcium antagonist and β-adrenergic receptor blockers. J Cardiovasc Pharmacol 1991;18(suppl 9):S41-4.
27. Grunlich-Henn J, Muller-berghaus G. Regulation of endothelial tissue plasminogen activator and plasminogen activator inhibitor type 1 synthesis by diacylglycerol, phorbol ester and thrombin. Blut 1990;61:38-44.
28. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984;74:1465-72.
29. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87:1969-73.
30. Maqueda IG. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin and carvedilol. Coron Artery Dis 1994; 5:909-18.